Patient-reported outcomes of topical finasteride/minoxidil treatment for male androgenetic alopecia: A retrospective study using telemedical data.

Autor: Abeck F; Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hansen I; Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Kött J; Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schröder F; Wellster Healthtech Group, Munich, Germany., Garrahy E; Wellster Healthtech Group, Munich, Germany., Veneroso J; Wellster Healthtech Group, Munich, Germany., Rünger A; Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Torster L; Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schneider SW; Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., von Büren J; Wellster Healthtech Group, Munich, Germany.
Jazyk: angličtina
Zdroj: Journal of cosmetic dermatology [J Cosmet Dermatol] 2024 Sep; Vol. 23 (9), pp. 2956-2963. Date of Electronic Publication: 2024 May 07.
DOI: 10.1111/jocd.16360
Abstrakt: Background: Oral finasteride and topical minoxidil are the current standard of care for male androgenetic alopecia and a combination of the two treatments can be considered for greater efficacy. Clinical trials of topical finasteride have also yielded promising results, but routine care data are lacking.
Aims: To examine patient-reported outcomes of men with androgenetic alopecia who received topical finasteride admixed with minoxidil compared to the current standard of care (oral finasteride).
Methods: Retrospective, cross-sectional study with data from a German direct-to-consumer teledermatology platform between December 2021 and January 2023. Patient-reported outcomes were collected through voluntary follow-up questionnaires provided after 6 weeks on topical finasteride/minoxidil or oral finasteride treatment.
Results: A total of 1545 patients who received topical finasteride/minoxidil treatment were included; 238 (15.4%) participated in the follow-up questionnaire. At week six, 62.2% (148/238) reported positive changes in their hair appearance, and 44.1% (105/238) reported an improvement of self-esteem. Treatment-related adverse events were reported in 11.8% (28/238). Full treatment adherence was observed in 74.4% (177/238). Comparing the topical treatment group to those receiving oral finasteride, lower treatment adherence was reported, along with higher rates of local adverse events; no difference was found in the incidence of sexual adverse events.
Conclusion: Based on patient-reported outcomes, topical finasteride/minoxidil seems to be effective and well tolerated, but not superior to oral finasteride. Lower treatment adherence for topical usage must be considered when considering treatment options. Additional real-world data are needed to further evaluate the efficacy and safety of topical finasteride/minoxidil.
(© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje